Zentalis pharmaceuticals announces inducement grant under nasdaq listing rule 5635(c)(4)

San diego, feb. 03, 2025 (globe newswire) -- zentalis® pharmaceuticals, inc. (nasdaq: zntl), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on february 3, 2025, the compensation committee of zentalis' board of directors granted non-qualified stock options to purchase an aggregate of 35,000 shares of the company's common stock to one newly hired employee. the stock options were granted under the zentalis pharmaceuticals, inc. 2022 employment inducement incentive award plan (2022 inducement plan) as an inducement material to such individual's entering into employment with zentalis in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking